Effect of human milk as a treatment for dry eye syndrome in a mouse model.
OBJECTIVE
Dry eye syndrome (DES) affects millions of people worldwide. Homeopathic remedies to treat a wide variety of ocular diseases have previously been documented in the literature, but little systematic work has been performed to validate the remedies' efficacy using accepted laboratory models of disease. The purpose of this study was to evaluate the efficacy of human milk and nopal cactus (prickly pear), two widely used homeopathic remedies, as agents to reduce pathological markers of DES.


METHODS
The previously described benzalkonium chloride (BAK) dry eye mouse model was used to study the efficacy of human milk and nopal cactus (prickly pear). BAK (0.2%) was applied to the mouse ocular surface twice daily to induce dry eye pathology. Fluorescein staining was used to verify that the animals had characteristic signs of DES. After induction of DES, the animals were treated with human milk (whole and fat-reduced), nopal, nopal extract derivatives, or cyclosporine four times daily for 7 days. Punctate staining and preservation of corneal epithelial thickness, measured histologically at the end of treatment, were used as indices of therapeutic efficacy.


RESULTS
Treatment with BAK reduced the mean corneal epithelial thickness from 36.77±0.64 μm in the control mice to 21.29±3.2 μm. Reduction in corneal epithelial thickness was largely prevented by administration of whole milk (33.2±2.5 μm) or fat-reduced milk (36.1±1.58 μm), outcomes that were similar to treatment with cyclosporine (38.52±2.47 μm), a standard in current dry eye therapy. In contrast, crude or filtered nopal extracts were ineffective at preventing BAK-induced loss of corneal epithelial thickness (24.76±1.78 μm and 27.99±2.75 μm, respectively), as were solvents used in the extraction of nopal materials (26.53±1.46 μm for ethyl acetate, 21.59±5.87 μm for methanol). Epithelial damage, as reflected in the punctate scores, decreased over 4 days of treatment with whole and fat-reduced milk but continued to increase in eyes treated with nopal-derived materials.


CONCLUSIONS
Whole and fat-reduced human milk showed promising effects in the prevention of BAK-induced loss of corneal epithelial thickness and epithelial damage in this mouse model. Further studies are required to determine whether human milk may be safely used to treat dry eye in patients.
Department of Ophthalmology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Jose L
JL
Diego
Department of Ophthalmology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Luke
L
Bidikov
Department of Ophthalmology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Michelle G
MG
Pedler
Department of Ophthalmology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Jeffrey B
JB
Kennedy
Department of Ophthalmology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Hugo
H
Quiroz-Mercado
Department of Ophthalmology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Darren G
DG
Gregory
Department of Ophthalmology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
J Mark
JM
Petrash
Department of Ophthalmology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO 80045.
Emily A
EA
McCourt
Complement Ther Med. 2010 Dec;18(6):241-8
21130360
Chem Cent J. 2011 Mar 03;5(1):10
21371324
Pediatr Res. 1995 Apr;37(4 Pt 1):444-9
7596683
Ocul Surf. 2007 Apr;5(2):108-52
17508118
N Engl J Med. 2002 Dec 19;347(25):2046-56
12490687
J Pediatr. 1973 Jun;82(6):1082-90
4573989
J Sci Food Agric. 2011 Apr;91(6):1001-5
21287558
Mol Vis. 2011 Jan 25;17:257-64
21283525
J Pediatr (Rio J). 2015 Jan-Feb;91(1):36-43
25211380
Front Pharmacol. 2015 Nov 18;6:280
26635610
Molecules. 2014 Sep 17;19(9):14879-901
25232708
Am J Ophthalmol. 2004 Feb;137(2):337-42
14962426
Br J Ophthalmol. 1999 Apr;83(4):390-5
10434857
Toxicol Appl Pharmacol. 2008 Feb 15;227(1):125-35
18037151
Saudi J Ophthalmol. 2014 Jul;28(3):173-81
25278793
Invest Ophthalmol Vis Sci. 1987 Sep;28(9):1497-504
2442115
Arch Ophthalmol. 2008 Feb;126(2):219-25
18268213
Mol Vis. 2016 Apr 02;22:284-93
27110091
Invest Ophthalmol Vis Sci. 2012 Jan 20;53(1):191-7
22159022
Indian J Ophthalmol. 1999 Mar;47(1):15-8
16130279
Clin Ophthalmol. 2013;7:2131-5
24204115
Cornea. 1994 Nov;13(6):505-8
7842709
Diabetes Care. 2003 Apr;26(4):1277-94
12663610
Appl Environ Microbiol. 2010 Oct;76(20):6888-94
20802077
Ocul Surf. 2007 Apr;5(2):93-107
17508117
Front Biosci (Elite Ed). 2012 Jan 01;4:1669-82
22201984
J Food Sci. 2010 Aug 1;75(6):E347-52
20722919
Invest Ophthalmol Vis Sci. 1988 Nov;29(11):1671-6
3182202
Br J Ophthalmol. 1994 Nov;78(11):810-2
7848973
Ann Intern Med. 2003 Mar 4;138(5):393-9
12614092
Ocul Surf. 2013 Jul;11(3):181-92
23838019